Pluristem plans secondary Nasdaq offering

The stem cell company will make the offering on the basis of the shelf prospectus filed with the US Securities and Exchange Commission.

Pluristem Therapeutics Ltd. (Nasdaq:PSTI; DAX: PJT: PLTR) yesterday announced that it plans to hold a secondary offering of shares and warrants, on the basis of the shelf prospectus filed with the US Securities and Exchange Commission (SEC) in October 2011. The company did not announce the terms of the offering, including the price or number of shares and warrants to be offered.

Pluristem's share price fell 2.4% on Nasdaq yesterday, and a further 8.8% in after-hours trading, following the announcement, to $4.14, giving a market cap of $200 million. The TASE suspended trading in the share until the pricing of the offering, after the share price fell 7% to NIS 17.30 at the opening.

Pluristem will offer blocks of shares and warrants as units. The underwriters, Jefferies & Company Inc., Oppenheimer & Co. Inc., Needham & Company, LLC and Maxim Group LLC, will be offered over allotment options. Leader Capital Markets Ltd. is the company's financial adviser on the offering.

Published by Globes [online], Israel business news - www.globes-online.com - on September 13, 2012

© Copyright of Globes Publisher Itonut (1983) Ltd. 2012

Twitter Facebook Linkedin RSS Newsletters גלובס Israel Business Conference 2018